Thiruvananthapuram witnessed Union MoS Jitendra Singh propel India’s BioE3 vision forward, stressing biotech’s centrality in a bio-economic era. At BRIC-RGCB’s Akkulam site, post the cGMP facility foundation ceremony, he outlined the policy’s long-term strategy for development.
Highlighting nuclear medicine’s growth after liberalization, Singh advocated interdisciplinary collaborations with private players via the Nuclear Medical Mission for innovative applications. He dedicated the Recombinant Cells and Sensors national facility and inaugurated Science Day.
India’s trailblazing BioE3 policy, linking biotech to economic vitality, environmental health, and jobs, sets it apart globally. Singh tied this to the Biopharma Shakti Mission, noting biotech’s elevated status over ten years amid a bio-driven world economy.
Institutional strides at BRIC-RGCB in molecular biology, genomics, pathology, and cancer research have lured experts in sequencing and interdisciplinary fields. Dr. Rajesh Gokhale emphasized biotech’s role in advancement, with BioE3’s thematic sectors and HPV vaccine successes using local data.
Dr. T.R. Santhosh Kumar detailed 600-700 stable cell lines in the facility for cancer targeting, making it a key resource. The cGMP plant will democratize cell and gene therapies through cost efficiency.